Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 3—March 2020
Research

Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola

Jennifer K. Legardy-Williams1Comments to Author , Rosalind J. Carter1, Susan T. Goldstein, Olamide D. Jarrett, Elena Szefer, Augustin E. Fombah, Sarah C. Tinker, Mohamed Samai2, and Barbara E. Mahon2
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J.K. Legardy-Williams, R.J. Carter, S.T. Goldstein, O.D. Jarrett, S.C. Tinker, B.E. Mahon); University of Illinois at Chicago, Chicago, Illinois, USA (O.D. Jarrett); The Emmes Corporation (E. Szefer); University of Sierra Leone College of Medicine and Allied Health Sciences, Freetown, Sierra Leone (A.E. Fombah, M. Samai)

Main Article

Figure 2

Number of pregnancies by estimated date of conception relative to vaccination or enrollment among 81 participants in the Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE). A) Immediate vaccination group (n = 31). B) Deferred crossover vaccination group (n = 17). C) Unvaccinated group (n = 33). Because pregnancy outcome for 3 of the 84 women unknown, these 3 women are not included in the figure. Outcomes include live birth (term and preterm) and pregnancy loss (early and late loss)

Figure 2. Number of pregnancies by estimated date of conception relative to vaccination or enrollment among 81 participants in the Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE). A) Immediate vaccination group (n = 31). B) Deferred crossover vaccination group (n = 17). C) Unvaccinated group (n = 33). Because pregnancy outcome for 3 of the 84 women was unknown, these 3 women are not included in the figure. Outcomes include live birth (term and preterm) and pregnancy loss (early and late loss). Gray shaded area denotes the high viremia risk period (i.e., women who were pregnant when vaccinated or became pregnant 0–14 days after vaccination).

Main Article

1These first authors contributed equally to this article.

2These authors were co–principal investigators.

Page created: February 20, 2020
Page updated: February 20, 2020
Page reviewed: February 20, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external